Latest News

Barcelona, Spain (UroToday.com) Dr. Cristina Suarez provided the invited discussion for the two kidney cancer studies presented, SORCE and TITAN-RCC. Dr. Suarez notes that adjuvant therapy in RCC is needed in that 30-40% of patients with high-risk features (high nuclear grade, locally advanced stage, and/or regional lymph node involvement) will experience disease recurrence. Indeed, antiangiogenics […]

Barcelona, Spain (UroToday.com) In this session, Ignacio Duran, MD, PhD, discussed the prior two sessions including 1) ENTRATA: Randomized, double-blind, phase 2 study of telaglenastat + everolimus vs. placebo + everolimus in patients with advanced/metastatic renal cell carcinoma (mRCC), and 2) Initial results from TROPHY-U-01: A Phase 2 open-label study of Sacituzumab Govitecan in patients […]

Barcelona, Spain (UroToday.com) In this session, Dr. Cristina Suarez discussed the prior two sessions including 1) Primary efficacy analysis results from the SORCE trial: Adjuvant sorafenib for renal cell carcinoma (RCC) at intermediate or high risk of relapse: an international, randomised double-blind Phase 3 trial, and 2) results from the Tailored ImmunoTherapy Approach with Nivolumab […]

Barcelona, Spain (UroToday.com) Four large, randomized Phase 3 clinical trials (S-TRAC, ASSURE, PROTECT, and ATLAS) evaluated adjuvant VEGF tyrosine kinase inhibitors in patients with resected renal cell carcinoma (RCC). Only S-TRAC met the primary endpoint of improvement in disease-free survival (DFS). None of these studies demonstrated improvement in overall survival (OS). Dr. Tim Eisen presents […]

Barcelona, Spain (UroToday.com) Professor Jan Oldenburg from Oslo, Norway provided a discussion of Dr. Silke Gillessen’s update of the International Germ Cell Cancer Collaborative Group (IGCCCG) NSGCT risk groups at ESMO 2019 annual congress. As Dr. Oldenburg notes, the original IGCCCG prognostic factor-based staging system was published more than two decades ago in 1997.1 This […]

Barcelona, Spain (UroToday.com) Treatment options for advanced urothelial cancers (UC) are limited, and the development of more effective therapies is a clear unmet need. In this session, Dr. Loriot discussed the previous two presentations: EV-103 looking at the combination of enfortumab vedotin (EV) and pembrolizumab as first line therapy in locally advanced and metastatic UCs, […]

Barcelona, Spain (UroToday.com) First-line therapy for metastatic renal cell carcinoma (mRCC) has rapidly evolved over the past decade. First, VEGF tyrosine kinase inhibitors (TKIs), then immunotherapy (IO), demonstrated a survival benefit in the first-line treatment setting. Most recently VEGF TKI plus IO combination regimens were found to be more effective than VEGF TKI alone. In […]

Barcelona, Spain (UroToday.com)  Enfortumab vedotin is an antibody-drug conjugate comprised of the nectin-4 antibody enfortumab coupled to the microtubule disrupting agent monomethyl auristatin E (MMAE). In preclinical models, MMAE-based antibody drug conjugates were shown to be capable of inducing immunogenic cell death, thereby augmenting the anti-tumor immune response.1 Furthermore, a recently published single-arm phase II […]